Polyrizon Ltd. Ordinary Shares (PLRZ) Dividend History

Company News

• US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert

  U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.

  Benzinga

  Featured Companies: BON CMI F FFAI HSIC QQQ RNAZ SPY TSN
• Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

  Polyrizon, a biotech company, has initiated preclinical studies for intranasal Naloxone, a treatment for opioid overdose, using its Trap and Target (T&T) platform. The studies aim to assess key parameters like drug loading, release kinetics, and nasal deposition, paving the way for further safety and efficacy testing.

  GlobeNewswire Inc.
• Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

  Polyrizon, a biotech company, announced the filing of a divisional patent application for its Trap & Target (T&T) intranasal drug delivery platform. The T&T platform aims to enhance the effectiveness of medications by increasing their residence time and bioavailability.

  GlobeNewswire Inc.
• Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

  Polyrizon, a biotech company, has signed a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to supply Clinical Trial Material for its PL-14 allergy blocker in preparation for a planned 2025 clinical trial.

  GlobeNewswire Inc.